AmirAli Talasaz is the co-CEO and co-founder of Guardant Health, a leading precision oncology company he co-founded in 2012 with Dr. Helmy Eltoukhy. Under AmirAli’s leadership, Guardant is transforming cancer care through advanced blood tests that discover cancer sooner and guide more precise treatment. Talasaz has been recognized by TIME100 Health as one of the most influential people in global health, Fortune (40 under 40), was named to Time Magazine’s inaugural list of the 50 Most Influential People in Health Care, and was a recipient of the PMWC Luminary Award in 2024 for his work advancing the science of cancer care and screening. Prior to co-founding Guardant Health, Talasaz founded Auriphex Biosciences, a biotech focused on purification and genomic analysis of circulating tumor cells for cancer management, whose technology was acquired by Illumina in 2009. At Illumina, he served as senior director of Diagnostics Research and led the efforts for emerging clinical applications of next-generation genomic analysis. Talasaz is a named inventor on more than 200 patents in liquid biopsy and circulating tumor DNA technologies and an author of over 40 publications. He holds a BS in electrical engineering from Sharif University of Technology, and an MS in management science and PhD in electrical engineering from Stanford University.